“Merck later admitted its lawsuit had no merit because it had failed to disclose prior art to the United States Patent and Trademark Office that would have resulted in the denial of patent protection for Zetia,” the complaint said. “But simply by initiating the litigation, Merck triggered a 30-month stay, which precluded the Food & Drug Administration from granting final approval of Glenmark’s ANDA.”